Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells

Cancer Science

Volumn 105, Issue 4, 2014, Pages 389-395

  Morita, Rena ^a   Nishizawa, Satoshi ^a,b   Torigoe, Toshihiko ^a   Takahashi, Akari ^a   Tamura, Yasuaki ^a   Tsukahara, Tomohide ^a   Kanaseki, Takayuki ^a   Sokolovskaya, Alice ^a   Kochin, Vitaly ^a   Kondo, Toru ^c   Hashino, Satoshi ^c   Asaka, Masahiro ^c   Hara, Isao ^b   Hirohashi, Yoshihiko ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Cancer stem like cell; Colorectal cancer; DNAJB8; Tumor antigen

Indexed keywords

CELL SURFACE MARKER; GAMMA INTERFERON; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN DNAJB 8; LGR5 PROTEIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; VERAPAMIL;

ADOPTIVE TRANSFER; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISTANT METASTASIS; HUMAN; HUMAN CELL; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CANCER IMMUNOTHERAPY; CANCER STEM-LIKE CELL; COLORECTAL CANCER; DNAJB8; TUMOR ANTIGEN;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP40 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84898416242     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12362     Document Type: Article

References (31)

1. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
2. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
3. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-13.
4. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
6. Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 2010; 116: 2071-80.
7. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
8. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24.
9. Honma I, Kitamura H, Torigoe T et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009; 58: 1801-7.
10. Kameshima H, Tsuruma T, Torigoe T et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 2011; 102: 1181-7.
11. Miyazaki A, Kobayashi J, Torigoe T et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 2011; 102: 324-9.
12. Kameshima H, Tsuruma T, Kutomi G et al. Immunotherapeutic benefit of IFNalpha in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013; 104: 124-9.
13. Hirohashi Y, Torigoe T, Inoda S et al. The functioning antigens: beyond just as the immunological targets. Cancer Sci 2009; 100: 798-806.
14. Hageman J, Rujano MA, van Waarde MA et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 2010; 37: 355-69.
15. Sterrenberg JN, Blatch GL, Edkins AL. Human DNAJ in cancer and stem cells. Cancer Lett 2011; 312: 129-42.
16. Nishizawa S, Hirohashi Y, Torigoe T et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012; 72: 2844-54.
17. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-806.
18. Inoda S, Hirohashi Y, Torigoe T et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011; 178: 1805-13.
19. Nakao M, Shichijo S, Imaizumi T et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 2565-74.
20. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
21. Inoda S, Hirohashi Y, Torigoe T et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009; 32: 474-85.
22. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-13.
23. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-63.
24. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
25. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
26. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-9.
27. Burkert J, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol 2008; 214: 564-73.
28. Todaro M, D'Asaro M, Caccamo N et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182: 7287-96.
29. Ning N, Pan Q, Zheng F et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012; 72: 1853-64.
30. Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V, Sato N. Cytotoxic T lymphocytes: sniping cancer stem cells. Oncoimmunology 2012; 1: 123-5.
31. Yamada R, Takahashi A, Torigoe T et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013; 81: 428-34.